TGTX
TG Therapeutics, Inc.
15.21
USD
This page is just a preview of the data found in TrendSpider’s full version
TG Therapeutics, Inc. stock is up 48.83% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 06 Dec 19:57 | 19 Jan, 2024 | 19.00 | 27 | ||
| 07 Dec 14:31 | 16 Feb, 2024 | 16.00 | 250 | ||
| 07 Dec 16:07 | 19 Jan, 2024 | 15.00 | 4666 | ||
| 07 Dec 16:12 | 19 Jan, 2024 | 15.00 | 4666 | ||
| 07 Dec 16:12 | 19 Jan, 2024 | 15.00 | 4666 | ||
| 07 Dec 18:18 | 17 Jan, 2025 | 22.00 | 477 | ||
| 08 Dec 17:35 | 17 May, 2024 | 14.00 | 54 | ||
| 08 Dec 20:14 | 16 Feb, 2024 | 20.00 | 2728 | ||
| 11 Dec 17:28 | 19 Jan, 2024 | 16.00 | 1880 | ||
| 11 Dec 17:29 | 15 Dec, 2023 | 18.50 | 250 |
TG Therapeutics, Inc. focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor.
